**Abstract**

**Background:** Aripiprazole is a D~2~ receptor (D~2~R) partial agonist with a favourable clinical profile, compared with other antipsychotics. Previous *in vivo* studies indicated that acute and short-term administration with aripiprazole affected the GSK3β (glycogen synthase kinase 3β)-dependent pathways, NMDA receptor and CREB (cAMP-responsive element-binding protein 1), which may contribute to its therapeutic efficacy. Aripiprazole is widely used for chronic treatment of various mental disorders, however the chronic effects of aripiprazole on cellular signalling are not clear.

**Aim:** The present study investigated the chronic effects of aripiprazole on the relevant signalling pathways, in comparison with haloperidol (a D~2~R antagonist) and bifeprunox (a potent D~2~R partial agonist).

**Method:** Rats were orally treated with aripiprazole (0.250 mg/kg), bifeprunox (0.267 mg/kg), haloperidol (0.033 mg/kg) or vehicle three times per day for 10 weeks. The levels of Akt (protein kinase B)-GSK3β, Dvl (dishevelled)-β-catenin, NMDA-CREB1 signalling pathways were measured in the prefrontal cortex (PFC), caudate putamen (CPu) and nucleus accumbens (NAc) by Western Blots.

**Results:** Akt-GSK3β pathway was activated by both aripiprazole and haloperidol in the PFC, and by all three drugs in the NAc. Both aripiprazole and bifeprunox increased the expression of Dvl-3 and β-catenin in the NAc. Both aripiprazole and haloperidol increased NMDA NR1 expression and CREB activity in the NAc; aripiprazole also promoted NMDA NR2A expression and CREB activity in the CPu.

**Conclusion:** All drugs tested had chronic effects on Akt-GSK3β signalling. Aripiprazole and haloperidol had similar effects on Dvl-β-catenin and NMDA-CREB signalling in the NAc, which indicates that a D~2~R partial agonist with relatively low intrinsic activity may affect Dvl-β-catenin and NMDA-CREB signalling. The chronic effects of aripiprazole on these signalling pathways may contribute to its long-term clinical efficacy.
